Join the club for FREE to access the whole archive and other member benefits.

Groundbreaking vaccines for cancer, cardiovascular, and autoimmune diseases could be ready by 2030

Covid-19 pushed through a decade's research and testing into a year, results of which could have much wider impact


Key points from article :

Pharmaceutical company Moderna is confident about offering such treatments within five years.

"I think we will be able to offer personalised cancer vaccines against multiple different tumour types to people around the world.” - Dr Paul Burton, chief medical officer of Moderna.

Covid-19 vaccine success has accelerated research in other disease areas.

“There has been a massive acceleration, not just of traditional vaccine technologies, but also novel ones that hadn’t previously been taken through licensure." - Dr Filip Dubovsky, president of R&D at Novavax

mRNA-based therapies show potential for rare diseases currently without drugs.

Scientists warn that continued high-level investment is necessary to maintain progress.

mRNA-based cancer vaccines can alert the immune system to destroy cancer without harming healthy cells.

Moderna's mRNA vaccine for RSV received breakthrough therapy designation from the FDA.

Pfizer is conducting a late-stage clinical trial for an mRNA-based influenza vaccine and has plans for other infectious diseases.

Mentioned in this article:

Click on resource name for more details.

Filip Dubovsky

Executive Vice President, Chief Medical Officer, President Research and Development at Novavax


Deliver on the promise of mRNA science to create a new generation of transformative medicines for patients


Company producing next-generation vaccines with global access for more people

Paul Burton

Chief Medical Officer at Moderna


Company developing, producing and marketing affordable, high quality generic drugs and specialty pharmaceuticals

Topics mentioned on this page:
Groundbreaking vaccines for cancer, cardiovascular, and autoimmune diseases could be ready by 2030